Article
Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
European journal of cancer (Oxford, England : 1990) - 1 Nov 2015
Spindler Karen-Lise Garm, Pallisgaard Niels, Appelt Ane Lindegaard, Andersen Rikke Fredslund, Schou Jakob V, Nielsen Dorte, Pfeiffer Per, Yilmaz Mette, Johansen Julia S, Hoegdall Estrid V, Jakobsen Anders, Jensen Benny V
Abstract excerpt
BACKGROUND: Circulating cell-free DNA (cfDNA) in plasma is a mixture of DNA from malignant and normal cells, and can be used as a liquid biopsy to detect and quantify tumour specific mutations e.g. KRAS. We investigated the clinical value of KRAS mutations when detected in plasma compared to tumour in patients from metastatic colorectal cancer (mCRC) prior to anti-epidermal growth factor receptor (anti-EGFR)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.